Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

计划入组 217 人 · 首次发布于 2021 年 6 月 9 日

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

计划入组 100 人 · 首次发布于 2025 年 6 月 6 日

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

计划入组 61 人 · 首次发布于 2024 年 1 月 22 日

Taletrectinib

Nuvation Bio's IBTROZI Demonstrates Strong Commercial Performance with 432 New Patients in First Six Months

Taletrectinib Shows Consistent Efficacy Across ROS1+ NSCLC Subgroups Regardless of Prior Chemotherapy or Fusion Partner

Nuvation Bio's David Hung on Building a Pipeline of Best-in-Class Oncology Drugs